Aptinyx Inc. (NASDAQ:APTX) is reporting third quarter financial results on Thursday 12th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, APTX is expected to report 3Q20 loss of $ 0.29 per share from revenue of $ 0.41 million.
For the full year, analysts anticipate top line of $ 1.86 million, while looking forward to loss of $ 1.22 per share bottom line.
Previous Quarter Performance
Aptinyx Inc. unfold loss for the second quarter of $ 0.27 per share, from the revenue of $ 0.49 million. The consensus estimates are loss of $ 0.28 per share. The bottom line results beat street analysts by $ 0.01 or 3.57 percent.
Stock Performance
Shares of Aptinyx Inc. traded low $ -0.05 or -1.55 percent on Wednesday, reaching $ 3.17 with volume of 423.10 thousand shares. Aptinyx Inc. has traded high as $ 3.27 and has cracked $ 3.11 on the downward trend
The closing price of $ 3.17, representing a 101.25 % increase from the 52 week low of $ 1.60 and a 50.23 % decrease over the 52 week high of $ 6.47.
The company has a market capital of $ 199.91 million and is part of the Healthcare sector and Biotechnology industry.
Conference Call
Aptinyx Inc. will be hosting a conference call at 5:00 PM eastern time on 12th November 2020, to discuss its 3Q20 financial results with the investment community. The participants may dial, (833) 772-0394 U.S. or (236) 738-2205 Outside U.S., when prompted, enter passcode 9186375 in order to access the live audio call. A live webcast with presentations will be available on the Internet by visiting the Company website www.aptinyx.com
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic peripheral neuropathy, as well as in Phase II clinical trial for treating fibromyalgia. It is also developing NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat post-traumatic stress disorder; and NYX-458, an NMDAr modulator, which is in Phase I clinical study for the treatment of Parkinsons disease cognitive impairment.
